In vivo and in vitro measurements of the relationship of human squamous carcinomas to herpes simplex virus tumor-associated antigens.
An additional 244 unfiltered sera have now been studied in a series of controlled, coded tests to determine the relationship of squamous carcinomas of the head and neck and cervix to the presence of complement-fixing antibodies to herpesvirus-tumor-associated antigens (HSV-TAA) in both tumor-bearing and cured patients. Ninety % of sera from patients with squamous carcinomas had antibodies to HSV-TAA, in contrast to 11% of sera from patients with nonsquamous cancers and 4% of sera from noraml individuals. The temporal relationship of Stage 1 laryngeal carcinomas suggests that HSV-TAA appearance precedes the immune defects. An in vitro correlate of the previously demonstrated specific delayed hypersensitivity reactions in controlled skin tests of squamous carcinoma patients with HSV-TAA is reported. In leukocyte migration inhibition tests, the migration indices after incubation with HSV-TAA of peripheral blood leukocytes from patients with squamous carcinoma (x = 0.847) were in definite contrast to migration indices seen for normal leukocytes (x = 1.037) and patients with nonsquamous solid cancers (x = 1.03). Thus, these polypeptides elicit both humoral antibody response and cell-mediated reactivity.
D000912:Antibodies, Neoplasm; D000914:Antibodies, Viral; D000951:Antigens, Neoplasm; D002294:Carcinoma, Squamous Cell / Q000276:immunology*; D002464:Cell Migration Inhibition; D003168:Complement Fixation Tests; D000939:Epitopes; D005260:Female; D006258:Head and Neck Neoplasms / Q000276:immunology; D006801:Humans; D006968:Hypersensitivity, Delayed; D008214:Lymphocytes / Q000276:immunology; D018139:Simplexvirus / Q000276:immunology*; D002583:Uterine Cervical Neoplasms / Q000276:immunology*
D000912:Antibodies, Neoplasm; D000914:Antibodies, Viral; D000951:Antigens, Neoplasm; D000939:Epitopes